| Literature DB >> 33841946 |
Ze-Guo Zhuo1, Gang Li1,2, Tie-Niu Song1, Gu-Ha Alai1, Xu Shen1, Yun Wang1, Yi-Dan Lin1.
Abstract
BACKGROUND: Lymphadenectomy is an essential but challenging part of the surgical treatment for esophageal cancer. However, the previously reported learning curve for robotic esophagectomy primarily focused on only one surgical approach (McKeown or Ivor Lewis). However, both approaches must be mastered by a mature robotic surgical team to deal with different clinical conditions and satisfy patients' needs. This study aimed to show how an experienced esophageal surgical team became proficient in both McKeown and Ivor Lewis robotic esophagectomy.Entities:
Keywords: Esophageal cancer; learning curve; lymphadenectomy; robotic surgery
Year: 2021 PMID: 33841946 PMCID: PMC8024862 DOI: 10.21037/jtd-20-2862
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895
The baseline characteristics of the first 100 patients who underwent robot-assisted minimally invasive esophagectomy
| Variables | N=100 |
|---|---|
| Age (year old) | 61.89±7.71 |
| Gender | |
| Male | 84 (84%) |
| Female | 16 (16%) |
| BMI (kg/m2) | 23.10±3.61 |
| Diabetes | 5 (5%) |
| Hypertension | 26 (26%) |
| Tumor location | |
| Upper thorax | 13 (13%) |
| Middle thorax | 50 (50%) |
| Lower thorax | 37 (37%) |
| Histology | |
| Squamous cell carcinoma | 88 |
| Adenocarcinoma | 6 |
| Other | 6 |
| Pathologic T stage | |
| Tis | 1 |
| T1 | 20 |
| T2 | 24 |
| T3 | 49 |
| T4a | 6 |
| Pathologic N stage | |
| N0 | 52 |
| N1 | 26 |
| N2 | 15 |
| N3 | 7 |
| TNM stage | |
| 0 | 1 |
| I | 14 |
| II | 42 |
| III | 34 |
| IVa | 9 |
| Surgical approach | |
| McKeown | 69 |
| Ivor Lewis | 31 |
| Number of RCLN-LN | 2.19 ±2.31 |
| Number of Thoracic LN | 9.97±4.78 |
| Number of Abdomen LN | 10.66±6.87 |
| Number of Total LN | 20.63±8.30 |
BMI, body mass index; LN, lymph node; RLN-LN, recurrent laryngeal nerve lymph node.
Figure 1The CUSUM plot of the number of harvested thoracic lymph nodes in the first 100 cases of robot-assisted minimally invasive esophagectomy from a single surgical team. By visual assessment on the CUSUM plot, the learning curve was divided into 4 phases by three turning points (the 23rd case, the 45th case, the 77th case), after which the tendency of the CUSUM plot changed. The first phase consisted of the first 23 cases. In this phase, the CUSUM plot trended downward, which meant the number of harvested lymph nodes in most cases was beneath the mean value of the 100 cases. After the 23rd case, the CUSUM plot trended to rise up and reached a peak when it came to the 45th case. So the 24th to 45th made the second phase. Then, another decline occurred between the 46th to 77th cases. It was the 3rd phase. After the 3rd phase, the CUSUM value waved around zero, and the CUSUM plot becomes steady. It made the fourth phase. CUSUM, cumulative sum.
Comparison of patients’ characteristics and the number of harvested lymph nodes among the four learning phases
| Characteristics | Phase 1 (1st-23th) | Phase 2 (24th-45th) | Phase 3 (46th-77th) | Phase 4 (78th-100th) | P value |
|---|---|---|---|---|---|
| Age | 62.17±7.08 | 60.09±6.42 | 63.09±8.74 | 61.65±8.03 | 0.572 |
| BMI (kg/m2) | 23.19±2.90 | 22.80±2.53 | 22.88±4.81 | 23.60±3.32 | 0.872 |
| Female/male | 4/19 | 3/19 | 6/26 | 3/20 | 0.929 |
| Diabetes | 1 (4.3%) | 1 (4.5%) | 2 (6.3%) | 1 (4.3%) | 0.984 |
| Hypertension | 6 (26.1%) | 5 (22.7%) | 11 (34.4%) | 4 (17.4%) | 0.537 |
| Tumor location | 0.101 | ||||
| Upper | 5 (21.7%) | 2 (9.1%) | 6 (18.8%) | 0 (0.0%) | |
| Middle and lower | 18 (78.3%) | 20 (90.9%) | 28 (81.3%) | 23 (100.0%) | |
| Surgical approach | 0.000 | ||||
| Ivor Lewis | 0 (0.0%) | 3 (13.6%) | 14 (43.8%) | 14 (60.9%) | |
| McKeown | 23 (100%) | 19 (86.4%) | 18 (56.3%) | 9 (39.1%) | |
| Histology | 0.841 | ||||
| SCC | 21 (91.3%) | 20 (90.9%) | 27 (84.4%) | 20 (87.0%) | |
| Other | 2 (8.7%) | 2 (9.1%) | 5 (15.6%) | 3 (13.0%) | |
| RLN-LNs | 2.00±2.15 | 2.77±2.22 | 1.81±2.18 | 2.22±2.70 | 0.470 |
| Thoracic LNs | 8.22±3.24 | 13.05±5.64 | 8.66±3.61 | 10.61±5.28 | 0.001 |
| Abdomen LNs | 10.61±8.34 | 10.86±6.24 | 10.06±6.83 | 11.35±6.23 | 0.923 |
| Total LN | 18.83±9.13 | 23.91±7.10 | 18.72±8.25 | 21.96±7.85 | 0.076 |
| T stage | 0.608 | ||||
| T0-T2 | 12 (52.2%) | 9 (40.9%) | 12 (37.5%) | 12 (52.2%) | |
| T3-T4a | 11 (47.8%) | 13 (59.1%) | 20 (62.5%) | 11 (47.8%) | |
| N stage | 0.760 | ||||
| N0-N1 | 19 (82.6%) | 18 (81.8%) | 23 (71.9%) | 18 (78.3%) | |
| N2-N3 | 4 (17.4%) | 4 (18.2%) | 9 (28.1%) | 5 (21.7%) | |
| TNM Stage | 0.583 | ||||
| 0-II | 12 (52.2%) | 12 (54.5%) | 17 (53.1%) | 16 (70.0%) | |
| III-IVa | 11 (47.8%) | 10 (45.5%) | 15 (46.9%) | 7 (30.0%) |
BMI, body mass index; SCC, squamous cell carcinoma; LN, lymph node; RLN-LN, recurrent laryngeal nerve lymph node.
Figure 2The CUSUM plot of the number of harvested thoracic lymph nodes in ro-bot-assisted McKeown and Ivor Lewis esophagectomy separately. (A) The CUSUM plot of the number of harvested thoracic lymph nodes in the first 31 cases of robot-assisted McKeown esophagectomy. The tendency of the CUSUM plot changed from downward to upward in the 23rd case. It indicated that it took 23 cases for the surgeons to accomplish the initial exploration of the harvest of the thoracic lymph nodes in the McKeown approach. (B) The CUSUM plot of the number of harvested thoracic lymph nodes in the first 31 cases of robot-assisted Ivor Lewis esophagectomy. The CUSUM plot tended to downward at the beginning, and it reached the lowest point in the 18th case. After that, the CUSUM plot started ascending. It indicated that on the basis of the robot-assisted McKeown lymphade-nectomy, the exploration of the thoracic lymphadenectomy in the Ivor Lewis approach took another 18 cases. CUSUM, cumulative sum.
Comparison of lymphadenectomy between McKeown and Ivor Lewis RAMIE in the learning and commanding phase
| Characteristics | Learning phase of | Commanding phase of | |||||
|---|---|---|---|---|---|---|---|
| M-RAMIE | IV-RAMIE | P value | M-RAMIE | IV-RAMIE | P value | ||
| Age | 62.17±7.08 | 63.44±8.77 | 0.610 | 61.67±7.38 | 60.00±8.77 | 0.491 | |
| BMI (kg/m2) | 23.19±2.90 | 22.80±2.53 | 0.483 | 22.62±3.05 | 23.04±2.32 | 0.643 | |
| Female/male | 4/19 | 3/15 | 1.000 | 8/38 | 1/12 | 0.668 | |
| Diabetes | 1 (4.3%) | 2 (11.1%) | 0.573 | 2 (4.3%) | 0 (0.0%) | 1.000 | |
| Hypertension | 6 (26.1%) | 5 (27.8%) | 0.903 | 12 (26.1%) | 3 (23.1%) | 1.000 | |
| Tumor location | 0.056 | 0.180 | |||||
| Upper | 5 (21.7%) | 0 (0.0%) | 8 (17.4%) | 0 (0.0%) | |||
| Middle and lower | 18 (78.3%) | 18 (100.0%) | 38 (82.6%) | 13 (100.0%) | |||
| RLN-LNs | 2.00±2.15 | 0.17±0.38 | 0.001 | 3.37±2.16 | 0.92±2.06 | 0.001 | |
| Thoracic LNs | 8.22±3.24 | 7.56±3.07 | 0.511 | 11.96±5.38 | 9.38±4.11 | 0.117 | |
| Abdomen LNs | 10.61±8.34 | 11.28±6.22 | 0.778 | 9.98±6.32 | 12.31±7.22 | 0.260 | |
| Total LN | 18.83±9.13 | 18.83±7.29 | 0.998 | 21.93±8.47 | 21.69±7.28 | 0.926 | |
| T stage | 0.063 | 0.701 | |||||
| T0-T2 | 12 (52.2%) | 4 (22.2%) | 22 (47.8%) | 7 (53.8%) | |||
| T3-T4a | 11 (47.8%) | 14 (77.8%) | 24 (52.2%) | 6 (46.2%) | |||
| N stage | 0.087 | 0.019 | |||||
| N0-N1 | 19 (82.6%) | 10 (55.6%) | 41 (89.1%) | 8 (61.5%) | |||
| N2-N3 | 4 (17.4%) | 8 (44.4%) | 5 (10.9%) | 5 (38.5%) | |||
| TNM stage | 0.116 | 0.059 | |||||
| 0-II | 12 (52.2%) | 5 (27.8%) | 34 (73.9%) | 6 (46.2%) | |||
| III-IVa | 11 (47.8%) | 13 (72.2%) | 12 (26.1%) | 7 (53.8%) | |||
BMI, body mass index; LN, lymph node; RLN-LN, recurrent laryngeal nerve lymph node.